Monoclonal enolase-1 blocking antibody ameliorates pulmonary inflammation and fibrosis.

"Declarations Ethics approval and consent to participateHuman peripheral blood was collected from healthy volunteers who gave written consent with specific approval from the Institutional Review Board of the Development Center of Biotechnology (DCB) (DCB-IRB-110012). Animal experiments were carried out in strict accordance with the approved protocols from the Institutional Animal Care and Use Committee (IACUC) of TFBS Bioscience (IACUC No. TFBS2020-007 and TFBS2023-003). Consent for publicationNot applicable. Competing interestsTTY is advisor at HuniLife Biotechnology which is a clinical stage company developing ENO1 antibodies as therapeutics for cancers, inflammatory disorders, and fibrotic diseases. TTY, WCH, ICC, CFC, MLC, and YTH are inventors on pending patent application for the use of ENO1 antagonists as anti-fibrotic agents. The authors declare that they have no competing interests. Competing interests TTY is advisor at HuniLife Biotechnology which is a clinical stage company developing ENO1 antibodies as therapeutics for cancers, inflammatory disorders, and fibrotic diseases. TTY, WCH, ICC, CFC, MLC, and YTH are inventors on pending patent application for the use of ENO1 antagonists as anti-fibrotic agents. The authors declare that they have no competing interests."

"Funding This work was supported by HuniLife Biotechnology Inc."